M. Petillon

发表

Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 ( hA 20): Phase I/II Results.

J. Leonard, B. Coiffier, M. Dyer, 2006 .

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

M. Mohty, P. Moreau, H. Avet-Loiseau, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

J. Leonard, B. Coiffier, M. Dyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.

D. Huglo, M. Pfreundschuh, L. Trümper, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)

J. Mary, P. Moreau, H. Avet-Loiseau, 2009 .

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

O. Decaux, P. Moreau, H. Avet-Loiseau, 2021, Leukemia.

Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y

D. Huglo, F. Kraeber-Bodéré, J. Chatal, 2008 .

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

B. Pégourié, O. Decaux, P. Moreau, 2015, Blood.

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

B. Pégourié, O. Decaux, P. Moreau, 2013, Blood.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

O. Decaux, A. Duhamel, P. Moreau, 2019, Clinical Cancer Research.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

B. Pégourié, O. Decaux, P. Moreau, 2015, Annals of Hematology.

Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02

B. Pégourié, A. Duhamel, P. Moreau, 2010 .

Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study

P. Cony-Makhoul, O. Decaux, C. Dumontet, 2023, American journal of hematology.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

B. Pégourié, O. Decaux, P. Moreau, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

B. Pégourié, O. Decaux, P. Moreau, 2011 .

Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)

B. Pégourié, O. Decaux, P. Moreau, 2013 .

Lenalidomide is safe and active in Waldenström macroglobulinemia

G. Salles, P. Morel, X. Leleu, 2015, American journal of hematology.

Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.

J. Leonard, B. Coiffier, D. Goldenberg, 2005 .

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM)

P. Morel, X. Leleu, V. Leblond, 2014 .

Hevylite® to Monitor Response to Therapy in Multiple Myeloma

B. Pégourié, O. Decaux, P. Moreau, 2014 .

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial

M. Mohty, P. Moreau, H. Avet-Loiseau, 2019, British journal of haematology.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

B. Pégourié, P. Cony-Makhoul, O. Decaux, 2015, Haematologica.

IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma

S. Harding, P. Moreau, H. Avet-Loiseau, 2014, Cancer.

[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

I. Yakoub-Agha, J. Larghero, M. Deschamps, 2017, Bulletin du Cancer.

Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma

P. Moreau, M. Macro, X. Leleu, 2023, British journal of haematology.

Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial

B. Pégourié, O. Decaux, P. Moreau, 2012 .

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study.

O. Decaux, P. Moreau, H. Avet-Loiseau, 2023, Haematologica.

Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).

S. Leyvraz, P. Moreau, H. Avet-Loiseau, 2009 .

Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL.

J. Leonard, B. Coiffier, D. Goldenberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol.

B. Pégourié, O. Decaux, P. Moreau, 2012 .

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

O. Decaux, P. Moreau, X. Leleu, 2015 .

The impact of an agricultural development project on a tropical forest environment: the case of Shaba (Zaïre)

Michel Massart, Eléonore Wolff, E. Wolff, 1995 .

Lenalidomide is safe and active in Waldenström macroglobulinemia

G. Salles, P. Morel, X. Leleu, 2015, American journal of hematology.

M. Mohty, P. Moreau, H. Avet-Loiseau, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.